MaxCyte Completes Operational Review, Adjusts Workforce, and Raises 2024 Revenue Guidance
MaxCyte completes operational review, streamlines workforce, increases 2024 revenue guidance, and focuses on cell therapy innovation.Quiver AI SummaryMaxCyte, Inc. has completed an internal operational...
Why Shares of MaxCyte Are Plummeting on Thursday
The biotech company reduced full-year guidance and expects so-so third-quarter revenue.
Nasdaq Futures Slip as Bond Yields Rebound, U.S. Jobs Report Looms
December Nasdaq 100 E-Mini futures (NQZ23) are trending down -0.10% this morning after three major U.S. benchmark indices closed higher on Wednesday as the latest batch of U.S. economic data prompted investors...